EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Daily vs. monthly oral vitamin D 3 for treatment of symptomatic vitamin D deficiency in infants: a randomized controlled trial

Anupriya Gora, Preeti Singh, Ekta Debnath, Rajeev Kumar Malhotra, Anju Seth iD

Journal of Pediatric Endocrinology and Metabolism · 26.07.2023 · 36 (7) · 683-691

DOI: 10.1515/jpem-2023-0146 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, online erschienen am 18.05.2023. Verfasst von Anupriya Gora und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lady Hardinge Medical College, New Delhi, India. Hauptthemen laut MEDLINE: Cholecalciferol, Vitamin D Deficiency. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Compare the efficacy and safety of daily vs. monthly oral vitamin D 3 in treating symptomatic vitamin D deficiency in infants.

Methods

90 infants with symptomatic vitamin D deficiency were randomized into Daily (D) [46 infants] and Bolus (B) [44 infants] groups to receive oral vitamin D 3 , daily (2000 IU/day) and bolus (60,000 IU/month) for three months respectively. Both groups received daily oral calcium @50 mg/kg/day. Serum calcium (Ca), phosphate (P), alkaline phosphatase (ALP), 25-hydroxy cholecalciferol [25(OH)D], parathyroid hormone (PTH) levels, urine calcium: creatinine ratio and radiological score were assessed at baseline, 4 and 12 weeks. At the end of 12 weeks, 78 infants were available for evaluation of efficacy and safety of both regimens.

Results

Both regimens led to a statistically significant increase in Ca and P levels and fall in ALP and PTH levels from baseline to 4 and 12 weeks of therapy, with no inter-group difference. Infants in group D had statistically significant higher mean 25(OH)D levels as compared to group B at 4 weeks (group D 130.89 ± 43.43 nmol/L, group B – 108.25 ± 32.40 nmol/L; p – 0.012) and 12 weeks (group D – 193.69 ± 32.47 nmol/L, group B – 153.85 ± 33.60 nmol/L; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholecalciferolVitamin D DeficiencyInfantHumansCalciumCalcifediolParathyroid HormoneAlkaline PhosphataseVitamin DDietary SupplementsCalcium Radioisotopes

Stichwörter der Autor:innen

infancyoral supplementationrandomized controlled trialricketsvitamin D deficiency

Substanzen

CholecalciferolCalciumCalcifediolParathyroid HormoneAlkaline PhosphataseVitamin DCalcium-50Calcium Radioisotopes

Autor:innen und Institutionen

  • Lady Hardinge Medical College, New Delhi, India.
  • Department of Pediatrics, Lady Hardinge Medical College, New Delhi, India.
  • Department of Biochemistry, Lady Hardinge Medical College, New Delhi, India.
  • Department of Delhi Cancer Registry, BR Ambedkar IRCH, All India Institute of Medical Sciences, New Delhi, India.

ORCID-Profile: Anju Seth

Zitieren

APA

Gora, A., Singh, P., Debnath, E., Malhotra, R. K., & Seth, A. (2023). Daily vs. monthly oral vitamin D 3 for treatment of symptomatic vitamin D deficiency in infants: a randomized controlled trial. Journal of Pediatric Endocrinology and Metabolism, 36(7), 683-691. https://doi.org/10.1515/jpem-2023-0146

Vancouver

Gora A, Singh P, Debnath E, Malhotra RK, Seth A. Daily vs. monthly oral vitamin D 3 for treatment of symptomatic vitamin D deficiency in infants: a randomized controlled trial. Journal of Pediatric Endocrinology and Metabolism. 2023;36(7):683-691. doi:10.1515/jpem-2023-0146

BibTeX
@article{Gora2023,
  author = {Gora, Anupriya and Singh, Preeti and Debnath, Ekta and Malhotra, Rajeev Kumar and Seth, Anju},
  title = {Daily vs. monthly oral vitamin D 3 for treatment of symptomatic vitamin D deficiency in infants: a randomized controlled trial},
  journal = {Journal of Pediatric Endocrinology and Metabolism},
  year = {2023},
  volume = {36},
  number = {7},
  pages = {683--691},
  doi = {10.1515/jpem-2023-0146}
}
Kostenlos starten →